William Blair acted as the exclusive financial advisor to EQT in connection with its pending acquisition of Mabtech. The transaction was announced on January 9, 2024 with closing expected in Q1 2024 and marks the first investment of the newly introduced EQT Healthcare Growth Strategy.
About the Companies
EQT is a purpose-driven global investment organization with EUR 232 billion in total assets under management (EUR 128 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence, and market leadership.
Mabtech is a Swedish company developing immunoassays for life science research. Since 1986, Mabtech’s mission has been to aid research by providing the global scientific community with innovative tools. To that end, the company generates and produces a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications.